Medcast’s Post

🧐 Are you seeing more patients who are either using or considering GLP-1/GIP agonists? Or maybe you’ve been asked how to support their body’s natural production of incretins? Join Jocelyn Strand, ND, our Senior Director of Clinical Education, at GastroANP's annual conference to learn: ✅ The role these medications currently play ✅ New areas of activity being discovered ✅ How incretins are produced naturally and released in the gut This is a must-attend for any practitioner looking to optimize patient outcomes in this fast-evolving space. We'll see you there! https://lnkd.in/gj44Ug2D #NaturopathicMedicine #GLP1 #GutHealth #GastroANP

It's a warm one today at the Clinical Pharmacy Congress ☀ Come and cool down with a cold drink and something to eat while learning about our Medicines Management solutions. 📌 Stand G35 ExCeL London Clinical Pharmacy Congress _________________________________________________________________________________ Sandeep Gusai Lorna Norris Ant Johnson Grant Witheridge Daryll Goodall #CPC24 #CPCongress24 #PharmacyCongress

Planning for Success - Preparing for Adversity with the 17th Annual Clinical Trial Supply West Coast 2024 in San Fran! #ClinicalTrials #LifeSciences #IndustryInnovation #ClinicalTrialSupply #LifeSciencesRecruitment

The FDA issued a draft guidance, Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies, to assist medical product sponsors in submitting Diversity Action Plans (DAP) to support certain clinical studies. Diversity Action Plans are intended to increase enrollment of underrepresented populations to improve the data the agency receives.   DTRA looks forward to creating a response with input from all members. Please join us for a moderated discussion on the DAP Guidance with the following agenda. This session will help craft a response to submit to the FDA. 📣 How does the DAP guidance help clarify what's expected and mitigate ambiguity in creating a diversity action plan. 📣 What is still unclear? 📣 How might DCTs help support achieving the DAP? We welcome all DTRA members to join this session! Contact secretariat@dtra.org to receive the invite. https://lnkd.in/g6cZqTte

Congratulations to our specialty pharmacy clinical outcomes team! AJHP has published our landmark study examining how HSSPs improve care for patients living with multiple sclerosis (PwMS): https://lnkd.in/gkjwEQFp It's the industry's first study to use real-world data to evaluate pharmacist-led clinical interventions for PwMS. "This research helps us measure where pharmacy can have an impact," the authors said in a recent blog post. "Importantly, it also helps all of us understand where PwMS need more support to improve outcomes in the future." 🔗 Learn more about the study: https://lnkd.in/gkjwEQFp 📌 Access the manuscript: https://lnkd.in/gEfgZC52 Alexis El-Khouri | Carly Giavatto, PharmD | Amanda Hickman | Casey Fitzpatrick | Jessica Mourani Doueiry | Kipp Tiger | Megan Rees, PharmD, BCACP, CSP | Ana Lopez-Medina CPS | ASHP #pharmacy #specialtypharmacy #HSSPoutcomes #multiplesclerosis #blog #healthcare

We are excited to announce the addition of eight new representatives to the Patient Engagement Collaborative (PEC), a joint initiative by the FDA and Clinical Trials Transformation Initiative (CTTI). These new members will bring diverse perspectives and experiences to enhance communication, education, and patient engagement in medical product regulation. The PEC, established in 2018, is a group of patient organizations and individual representatives who collaborate with the FDA to discuss ways to improve patient engagement. The new representatives were selected from 75 applications and will serve for two years, contributing to ongoing discussions on how patient perspectives can inform the clinical trials enterprise. https://bit.ly/4it7QP7

This webinar offers a comprehensive overview of Decentralized Clinical Trials (DCTs), focusing on foundational principles, feasibility assessments, and practical implementation strategies. Learn about launching successful DCTs from the sponsor's perspective, reviewing key components such as regulatory considerations, patient recruitment strategies, and necessary technological infrastructure. Register here ⇢ https://lnkd.in/dQ42ix_S

In the next few weeks, we would like to explain to you which road our patients would follow for an upcoming clinical trial. We call this “the process”. This week we’ll take a look at the second step: signing ICF.  Last week we’ve explained the pre-screening. At the end of the pre-screening, there is a first appointment made at Meclinas. At this first appointment at Meclinas, our doctor explains to the patient all the information about the upcoming trial. The patient will have time to think and discuss about all this matter with his general practitioner, family and/or friends. Once the patient feels confident to participate in the clinical trial, they will sign the ‘Informed Consent Form (ICF)' twice. The patient will receive 1 ICF to keep at home, while 1 ICF will remain at site. The whole ICF signature process is documented in our source documents. Meclinas is well aware that signing the ICF doesn’t mean that the patient has to finish the trial. They’ll just sign a confirmation that they received all the information about the trial AND that they had time to reflect about their participation AND they agree to participate in the trial.    We know very well that the patient can decide to stop with the trials without giving any reason, we will respect their choice and decision.   #process #clinical #trial #clinicaltrial #clinicaltrials #ICF #informed #consent #form #info #information #health #meclinas #mechelen #science #technology

🎓 Excited to share that I have successfully completed the NIDA Clinical Trials Network’s "Good Clinical Practice" module! 🎉 Filled with valuable clinical practice content, this course offered an in-depth understanding of the core concepts and practical elements involved in designing, executing, and analyzing clinical trials. It provided participants with the essential knowledge and skills required to effectively navigate the intricate process of clinical research. The Center for Clinical Trials Network (CCTN) in the USA oversees the National Drug Abuse Treatment Clinical Trials Network (CTN), which is a multi-site research initiative focused on behavioral, pharmacological, and integrated treatment interventions. This project aims to evaluate effectiveness across a variety of community-based treatment settings and diverse patient populations. #ClinicalTrials #GoodClinicalPractice #Certification #ResearchExcellence #NIDA

First patient in this highly interesting first-in-human phase 1 study